有机化学人才网 | 最新人才 | 最新职位 | 技术交易 | 药物合成 |
   
全站搜索: |
  您当前位置:网站首页 >> 药物合成路线图解
 

药物详细合成路线

Name Ganirelix acetate;Org-37462;RS-26306;Antagon;Orgalutran
Chemical Name N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[(ethylamino)(ethylimino)methyl]-D-lysyl-L-leucyl-N6-[(ethylamino)(ethylimino)methyl]-L-lysyl-L-prolyl-D-alaninamide diacetate
      N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-Nomega,Nomega-diethyl-D-homoarginyl-L-leucyl-Nomega,Nomega-diethyl-L-homoarginyl-L-prolyl-D-alaninamide diacetate
CAS 129311-55-3
Related CAS 124904-93-4 (free base)
Formula C84H121ClN18O17
Structure
Formula Weight 1690.46437
Stage 上市-2000
Company Roche (Originator), Organon (Licensee)
Activity/Mechanism Disorders of Sexual Function and Reproduction, Treatment of, ENDOCRINE DRUGS, Female Infertility, Agents for, GnRH (LHRH) Antagonists
Syn. Route 3
Route 1
the synthesis of ganirelix was performed using usual solid-state peptide synthesis with a beckman 990 or a 5.0 l vega 296 automated solid-phase peptide synthesizer. the synthesis was initiated by condensation of chloromethylated polystyrene/divinylbenzene resin (merrifieled resin) (ii) with boc-d-alanine (i) by means of cesium carbonate, giving boc-d-ala-resin (iii), which was submitted to successive cycles of deprotection with tfa or hcl and addition of a new protected amino acid by means of dcc or hobt. the following amino acids were added successively: boc-l-proline (iv), nalpha-boc-nomega,nomega-diethyl-l-homoarginine (vi), boc-l-leucine (viii), nalpha-boc-nomega,nomega-diethyl-d-homoarginine (x) and boc-l-tyrosine (xii), yielding successively the peptide resins (v), (vii), (ix), (xi) and (xiii).
List of intermediates No.
2,2,2-trifluoro-n-[(3r)-2-oxopyrrolidinyl]acetamide (i)
4-[4-(4-[[(2s,4r)-2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl)-1-piperazinyl]aniline (iv)
(2s)-2-[(1s,2r,3r)-4-(benzyloxy)-1,3-dihydroxy-2-methylbutyl]-5-hexenyl pivalate (v)
[(4s,6s)-3-[(benzyloxy)methyl]-1,4-dimethyl-2,9-dioxabicyclo[3.3.1]non-6-yl]methyl pivalate (vi)
[(4s,6s)-3-(hydroxymethyl)-1,4-dimethyl-2,9-dioxabicyclo[3.3.1]non-6-yl]methyl pivalate (vii)
[(4s,6s)-3-ethynyl-1,4-dimethyl-2,9-dioxabicyclo[3.3.1]non-6-yl]methanol (ix)
(4s,6r)-1,4-dimethyl-3-[(e)-2-(tributylstannyl)ethenyl]-2,9-dioxabicyclo[3.3.1]nonane-6-carboxylic acid (x)
3-(triethylsilyl)-2-propynal (xi)
(3r,4r)-4-methyl-1-(triethylsilyl)-5-hexen-1-yn-3-ol (xii)
((3r,4r)-3-[[tert-butyl(dimethyl)silyl]oxy]-4-methyl-5-hexen-1-ynyl)(triethyl)silane; tert-butyl(dimethyl)silyl (1r,2r)-2-methyl-1-[2-(triethylsilyl)ethynyl]-3-butenyl ether (xiii)
(4ar,4bs,6as,7s,9as,9bs,11ar)-n-ethyl-1,4a,6a-trimethyl-2-oxohexadecahydro-1h-indeno[5,4-f]quinoline-7-carboxamide (viii)
Reference 1:
    robinson, j.3rd; morgans, d.j.; bingenheimer, w.; arzeno, h.b.; temporary serine protection in solid phase synthesis of lh-rh analogs. int j pept protein res 1993, 41, 4, 342.
Reference 2:
    castaner, j.; leeson, p.; rabasseda, x.; ganirelix acetate. drugs fut 1999, 24, 4, 393.
Reference 3:
    nestor, j.j. jr.; mcclure, n.l. (syntex (usa), inc.); temporary minimal protection synthesis of lh-rh analogs. ep 0443532; jp 1992211096; us 5212288 .
Reference 4:
    nestor, j.j. jr.; vickery, b.h. (syntex (usa), inc.); nonapeptide and decapeptide analogs of lhrh as lhrh antagonists. ep 0277829; jp 1988201199; us 4801577 .
Reference 5:
    vickery, b.h. (syntex (usa), inc.); lhrh antagonist analogs and 19-nor-progestational steroids for therapy. ep 0301850 .

Route 2
the synthesis of ganirelix was performed using usual solid-state peptide synthesis with a the following amino acids were added successively to intermediate (xiii): n-boc-o-benzyl-l-serine (xiv), boc-(3-pyridyl)-d-alanine (xvi) and boc-4-chloro-d-phenylalanine (xviii), yielding successively the peptide resins (xv), (xvii) and (xix).
List of intermediates No.
3,3-diphenyl-1-propanamine (xiv)
((3r,4r)-3-[[tert-butyl(dimethyl)silyl]oxy]-4-methyl-5-hexen-1-ynyl)(triethyl)silane; tert-butyl(dimethyl)silyl (1r,2r)-2-methyl-1-[2-(triethylsilyl)ethynyl]-3-butenyl ether (xiii)
ethyl 3-(diethoxyphosphoryl)propanoate (xv)
ethyl (e,4r,5r)-5-[[tert-butyl(dimethyl)silyl]oxy]-4-methyl-7-(triethylsilyl)-2-hepten-6-ynoate (xvi)
(e,4r,5r)-5-[[tert-butyl(dimethyl)silyl]oxy]-4-methyl-7-(triethylsilyl)-2-hepten-6-yn-1-ol (xvii)
[3-[(1r,2r)-2-[[tert-butyl(dimethyl)silyl]oxy]-1-methyl-4-(triethylsilyl)-3-butynyl]-2-oxiranyl]methanol (xviii)
bromo[2-(2-methyl-1,3-dioxolan-2-yl)ethyl]magnesium (xix)
Reference 1:
    robinson, j.3rd; morgans, d.j.; bingenheimer, w.; arzeno, h.b.; temporary serine protection in solid phase synthesis of lh-rh analogs. int j pept protein res 1993, 41, 4, 342.
Reference 2:
    castaner, j.; leeson, p.; rabasseda, x.; ganirelix acetate. drugs fut 1999, 24, 4, 393.
Reference 3:
    nestor, j.j. jr.; vickery, b.h. (syntex (usa), inc.); nonapeptide and decapeptide analogs of lhrh as lhrh antagonists. ep 0277829; jp 1988201199; us 4801577 .
Reference 4:
    vickery, b.h. (syntex (usa), inc.); lhrh antagonist analogs and 19-nor-progestational steroids for therapy. ep 0301850 .
Reference 5:
    nestor, j.j. jr.; mcclure, n.l. (syntex (usa), inc.); temporary minimal protection synthesis of lh-rh analogs. ep 0443532; jp 1992211096; us 5212288 .

Route 3
the amino acid boc-(2-naphthyl)-d-alanine (xx) were added to intermediate (xix), yielding the peptide resin (xxi). when the integration of amino acids was completed, the peptide resin (xxi) was deprotected with tfa, acetylated with acetic anhydride and finally treated with ammonia in methanol in order to eliminate the resin matrix and form the final amide group.
List of intermediates No.
bromo[2-(2-methyl-1,3-dioxolan-2-yl)ethyl]magnesium (xix)
(2s,3s,4r,5r)-5-[[tert-butyl(dimethyl)silyl]oxy]-4-methyl-2-[2-(2-methyl-1,3-dioxolan-2-yl)ethyl]-7-(triethylsilyl)-6-heptyne-1,3-diol (xx)
(2s,3s,4r,5r)-5-[[tert-butyl(dimethyl)silyl]oxy]-3-hydroxy-4-methyl-2-[2-(2-methyl-1,3-dioxolan-2-yl)ethyl]-7-(triethylsilyl)-6-heptynyl pivalate (xxi)
Reference 1:
    robinson, j.3rd; morgans, d.j.; bingenheimer, w.; arzeno, h.b.; temporary serine protection in solid phase synthesis of lh-rh analogs. int j pept protein res 1993, 41, 4, 342.
Reference 2:
    castaner, j.; leeson, p.; rabasseda, x.; ganirelix acetate. drugs fut 1999, 24, 4, 393.
Reference 3:
    nestor, j.j. jr.; mcclure, n.l. (syntex (usa), inc.); temporary minimal protection synthesis of lh-rh analogs. ep 0443532; jp 1992211096; us 5212288 .
Reference 4:
    vickery, b.h. (syntex (usa), inc.); lhrh antagonist analogs and 19-nor-progestational steroids for therapy. ep 0301850 .
Reference 5:
    nestor, j.j. jr.; vickery, b.h. (syntex (usa), inc.); nonapeptide and decapeptide analogs of lhrh as lhrh antagonists. ep 0277829; jp 1988201199; us 4801577 .

来源:药化网

作者:药化小编

摘要:本文合成路线介绍的是药物中文名加尼瑞克;英文名Ganirelix acetate;Org-37462;RS-26306;Antagon;Orgalutran;CAS[129311-55-3]

 
推荐VIP企业
无锡景耀生物科技有限公司
杭州卢普生物科技有限公司
宁波赛伦化工有限公司
苏州昊赛生物科技有限公司
北京嘉盛扬医药科技有限公司
上海泽涵生物医药科技有限公司
河北固安三利化工公司
郑州凯普瑞生物技术有限公司
上海药谷药业有限公司
兰州康寓信生物科技有限公司
湖北朗昕生化药业有限公司
武汉福鑫化工有限公司
嘉兴市英南化工有限公司
苏州迪飞医药科技有限公司
北京富安凯科技有限公司
上海盛中医药化工有限公司
连云港天和化学有限公司
南京晨瑞医药科技有限公司
南京苏如化工有限公司
常州瑞盛化工有限公司
热门文章
华东地区甲苯行情暂稳
华北地区甲苯行情暂稳
山东地区三氯甲烷价格
华东地区环氧氯丙烷动态
华中地区甲苯行情暂稳
华北地区BDO市场观望整理
华南地区甲苯行情暂稳
华北地区BDO市场观望整理
山东地区木薯乙醇市场变动不大
华东地区BDO市场疲态难改
华南地区BDO市场商谈偏弱
东北地区甲苯行情下跌
华中地区甲苯行情暂稳
华东地区己二酸市场行情持稳
山东地区三氯甲烷价格
华南地区己二酸行情小幅调整
华北地区BDO市场观望整理
山东地区辛醇市场气氛清淡
华北地区丁二烯市场价格窄调
山东地区丙烷市场行情上涨
 友情链接
有机化学人才网  
首页 | 广告服务 | 建站服务 | 关于我们 | 联系我们 | 版权声明